MSD MSD
Company Profile ↓Company Overview
MSD (MSD) is a publicly traded company listed on with a market capitalization of $133.93M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 8.2.
Maintains a net profit margin of 97.5%.
Carries low leverage with a debt-to-equity ratio of 0.03.
Recent Developments
- Dec 2025 Revenue of $21.68M (+28.5% YoY); net profit $21.13M.
- Trailing 12 Months Year-on-year growth — revenue +28.5%, earnings +29.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 28.52% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 29.11% |
Stock Price Performance
| 1 Year: | -3.31% |
| 6 Months: | -6.36% |
| 3 Months: | -6.88% |
| 1 Month: | -2.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 97.5%.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | -37.25M | 17.50M | 16.87M | 21.68M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 341.00K | 511.00K | 506.00K | 554.00K |
| Operating Income | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -37.59M | 16.99M | 16.37M | 21.13M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -37.59M | 16.99M | 16.37M | 21.13M |
| Diluted EPS | -0.23 | -1.85 | 0.85 | 0.81 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 158.71M | 159.78M | 158.53M | 163.50M |
| Current Assets | - | - | - | - |
| Cash & Equivalents | 310.00K | 0 | 251.00K | 117.00K |
| Inventory | - | - | - | - |
| Receivables | 4.92M | 5.21M | 4.53M | 5.12M |
| Total Liabilities | 4.49M | 5.18M | 5.97M | 4.33M |
| Current Liabilities | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Total Debt | - | 52.00K | - | - |
| Total Equity | 154.21M | 154.60M | 152.56M | 159.16M |
| Shares Outstanding | 20.39M | 20.19M | 20.20M | 20.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | 100.9% | 97.1% | 97.0% | 97.4% |
| ROE % | - | -24.4% | 11.0% | 10.7% | 13.3% |
| ROCE % | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MSD
ESMO26: MSD and Moderna drop cancer vaccine trial data early - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPeWRBNVZJV0hhRXpjaU85Z28xUnRfc1JudE9NMUV1azItTlZ2Wlhta0JFUFRoYm5tak1kNFJLS0oyQk5pVDdjT3c1VTZlUF9JU09CclF1TDJQTWNpMkNHMzRWaFItMGd3cklZeEdybERxSzJ0NkttcVNMWmVZb0FjT0Nn?oc=5" target=…
Moderna Shares Plunge 26% Despite Cancer Vaccine Success - 조선일보
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNVGtxQXFMSFBDdVhlc2FSMGhXR2F0YzJMWjJyalg1SERIUVZXSXhGck1sZjVvM2RSaHp4Y0tYNTZxVXpNQ0VuazYxUU9rWHIxc0pmVFQxNGQ3SmhyTDNrWW9qNXlDZVVmNXVHc214UkVnWW5idE1jOXlOME1yei1GVEpQbVhtRnQ5?oc=5"…
(MSD) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOS0lzcGc2eWs4dUw5Zk83ZnIyZHhjVzNiV0hJUXpNOEVEVXcxdlpjSXktX01pS1pReGFkVHJOcDJTbjRNZmtXOW5QYUJYZTFRV0pidHk4elBxWlBCbExJajZBelZTUEwyejF2cEl5QWluUk9lUGUtblpQS0kzM2EzbDU1NEhTcGl2cFpka2…
Merck & (MRK) Stock Price, News & Analysis - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMiTEFVX3lxTFBLMS0yRUozdkdvRkFiSEF5NzFIMnFTV2pIWEllVDlOYmktcFF0NjBFMUpoOTZGWUEwNHA2TFpnTjBiY25PMG9YaEhfY1M?oc=5" target="_blank">Merck & (MRK) Stock Price, News & Analysis</a> <font …
Zero voting power accompanies a reported stake in Morgan Stanley Emerging Markets Debt Fund (MSD). - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPa1loMmgxd2lEcUdpUFlOTWpfQVJjS1RYdnNlZUM0MDBHQWt0dmpKTVVKR3EzUXhIMTU2eTdIZzB1NVItSlV2RjNjQ0V1ZDFkNnAxUUpQSXN2dDIycWxMbERHbXF1ZmlSYlNzUDJlSDBNWDc0ZHl0LXhnVFUxNFFOcUExaG9feXMxQkxGT2…
Mayor, city officals take stock after deadly flooding in Tri-State as cleanup begins - FOX19 | Cincinnati
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQQ21kWGpHQ0tlaUhjX2czWmFxR3Q1aFZES3dvQ2VraDEwb2M0YVlWSEM3dHdwOTJQb1B1clBsWXB5MzliNWlXMmNtWXkyaEY2cnVva0VOcXc5Y3kwTUlIbklmSFVVc0lKM0g2OERoWmd1ejQwaTA4SzlEZXVocl9XZTFmYkRDSzNoc1dGOV…
MSD — Frequently Asked Questions
What is the current share price of MSD?
As of 2026-10-23 16:27 PDT, MSD trades at $6.62 on NASDAQ/NYSE. Its 52-week range is $6.62 to $7.46.
What is the market capitalisation of MSD?
MSD has a market capitalisation of $133.93M on NASDAQ/NYSE.
What is the P/E ratio of MSD?
MSD trades at a trailing price-to-earnings (P/E) ratio of 8.17. Its price-to-book (P/B) ratio is 0.84.
What is the return on equity (ROE) of MSD?
MSD has a return on equity (ROE) of 13.28%.
Is MSD a good stock to buy?
This page provides a data-driven analysis of MSD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.